Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Appendicectomy in ulcerative colitis patients with primary sclerosing cholangitis

The effects of appendicectomy in inflammatory bowel disease require further study in order to identify any influence on the extent of colitis, concludes an Australian study in the latest issue of Gut.

News image

fiogf49gjkf04

Appendicectomy, like smoking, is known to influence the clinical behavior of ulcerative colitis. However, in patients with coexistent primary sclerosing cholangitis (PSC), the phenotype of their disease already differs from those patients with ulcerative colitis (UC) alone.

Researchers have therefore examined the interaction of appendicectomy and PSC on the epidemiology and clinical course of ulcerative colitis, to see what further differences may be observed.

Patients from the Brisbane IBS Research Group database were used to carry out the study, with controls taken from the Australian twin registry.

A total of 78 PSC-inflammatory bowel disease (PSC-IBD) patients, 12 pure PSC patients, and 294 UC patients were matched with 1466 controls by sex and birth cohort that comprised randomly selected twins from each twin pair.

Investigations were then carried out into the effects of appendicectomy, smoking, or PSC on various clinical factors.

These were onset of disease, disease extent, disease severity (as identified by immunosuppression-colectomy or liver transplant) and disease related complications. Disease related complications were classed as high grade dysplasia, colorectal cancer, or cholangiocarcinoma.

All investigations were analyzed using univariate and multiple logistic regression analyses.

The researchers found that PSC-IBD patients suffered from more extensive colitis that did UC patients, but required less immunosuppression, a finding which was independent of disease extent.

Furthermore, such patients had an increased likelihood of having high grade dysplasia or colorectal cancer than did UC patients.

Appendicectomy can influence ulcerative colitis
Gut

In the PSC groups there was no difference in appendicectomy rates when compared with the control group.

This contrasted dramatically with the UC patients, who were four times less likely to have undergone appendicectomy than were subjects from the control group.

When examining the affect of appendicectomy, there appeared to be an approximate five year delay in the onset of intestinal (PSC-IBD or UC) or hepatic (PSC) disease in those patients who had undergone prior appendicectomy. This finding was independent of smoking.

However, appendicectomy did not independently alter the extent or severity of disease in PSC.

This was not the case in UC, where prior appendicectomy was associated with more extensive disease but with a lesser requirement for immunosuppression or colectomy for the treatment of colitis.

Non-statistically significant trends for high grade dysplasia or colorectal cancer were identified with appendicectomy in both PSC-IBD and UC. Despite the lack of statistical significance, colorectal cancer appeared more frequent with appendicectomy in a meta-analysis of the available UC data from this and another Australian study.

The researchers conclude that unlike UC, appendicectomy did not significantly influence the prevalence of the PSC groups, or the extent of colitis in PSC-IBD. However, as with UC, appendicectomy did appear to delay their onset.

They add that extensive milder colitis, which is characteristic of PSC-IBD, relates to other poorly understood factors.

Further prospective studies, they say, are required to determine any influence of appendicectomy on the extent of colitis in IBD and an associated dysplasia or colorectal cancer.

Gut 2004; 53(7): 973
30 June 2004

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us